Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SH3I
|
|||
| Former ID |
DAP001318
|
|||
| Drug Name |
Bortezomib
|
|||
| Synonyms |
179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Velcade (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Approved | [1], [2] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Approved | [3], [4] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 3 | [3], [4] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H25BN4O4
|
|||
| Canonical SMILES |
B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
|
|||
| InChI |
1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
|
|||
| InChIKey |
GXJABQQUPOEUTA-RDJZCZTQSA-N
|
|||
| CAS Number |
CAS 179324-69-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
518755, 600019, 10276517, 11433362, 12015194, 14853748, 17137090, 17397304, 46508736, 50726119, 53787350, 56311715, 56311812, 56312401, 56313329, 56314055, 56314414, 56314469, 56314470, 57402302, 85096715, 87325438, 91611228, 99432365, 99443946, 103338073, 103963945, 104603020, 118048485, 118318599, 121360388, 124756934, 124950705, 125163741, 134340388, 135696579, 136023422, 136342479, 136367512, 136920302, 137030372, 141858114, 143497187, 144206183, 144206225, 152049125, 152239004, 152344341, 160829216, 160968549
|
|||
| ChEBI ID |
CHEBI:52717
|
|||
| ADReCS Drug ID | BADD_D00284 | |||
| SuperDrug ATC ID |
L01XX32
|
|||
| SuperDrug CAS ID |
cas=179324697
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cationic trypsinogen (PRSS1) | Target Info | Inhibitor | [5] |
| Kallikrein-related peptidase (KLK) | Target Info | Inhibitor | [5] | |
| Proteasome (PS) | Target Info | Modulator | [6] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pancreatic secretion | ||||
| Protein digestion and absorption | ||||
| Influenza A | ||||
| Reactome | Activation of Matrix Metalloproteinases | |||
| Cobalamin (Cbl, vitamin B12) transport and metabolism | ||||
| WikiPathways | Activation of Matrix Metalloproteinases | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007364) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391). | |||
| REF 4 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | |||
| REF 5 | Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. | |||
| REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.